Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novavax has reported favorable results from preclinical studies of its recombinant trivalent seasonal influenza virus-like particle vaccine, which is being developed by using recombinant VLP technology.
Subscribe to our email newsletter
The company’s pandemic influenza vaccine candidate is currently in Phase I/IIa clinical trials.
In a study using mice, two injections of Novavax’s trivalent seasonal flu vaccine without an adjuvant induced strong hemagglutination inhibition (HAI) antibody responses against all three influenza subtypes contained in the vaccine including H3N2, H1N1 and B. The study showed that when all three seasonal influenza virus-like particles (VLPs) were given as a single trivalent vaccine, the immune response to each subtype was comparable to that observed when the VLPs were given in a monovalent formulation.
Rahul Singhvi, Novavax’s president and CEO, said: “We are pleased that the results from this seasonal influenza vaccine preclinical study are in line with our expectations. We are aggressively moving this program forward to file an investigational new drug application (IND) as planned in the second quarter of 2008. If filed as anticipated, this would be our second vaccine IND within 12 months of our first vaccine IND, which we filed in June 2007 for our pandemic influenza VLP vaccine.”